Simultaneous determination of zopiclone and its two major metabolites (N-oxide and N-desmethyl) in human biological fluids by reversed-phase high-performance liquid chromatography.
A high-performance liquid chromatographic method has been developed for the simultaneous determination of zopiclone and its main metabolites (N-oxide and N-desmethyl derivatives) in biological fluids. After selective extraction (dichloromethane-2-propanol) these compounds are chromatographed on a column packed with Spherisorb ODS-2 (5 micron) using monobasic sodium phosphate-methanol (45:55, v/v). The eluted compounds are measured by fluorescence detection. The limit of detection of the method is 5 ng/ml for zopiclone in plasma and urine and 10 ng/ml for its two main metabolites (coefficient of variation less than 10%). This method has been successfully applied to pharmacokinetic studies of zopiclone and its two main metabolites in healthy subjects and patients with chronic renal failure.
D000293:Adolescent; D000328:Adult; D000368:Aged; D053961:Azabicyclo Compounds; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D006993:Hypnotics and Sedatives / Q000032:analysis* / Q000097:blood / Q000652:urine; D007676:Kidney Failure, Chronic / Q000097:blood / Q000652:urine; D007700:Kinetics; D008875:Middle Aged; D010879:Piperazines / Q000032:analysis* / Q000097:blood / Q000652:urine; D013050:Spectrometry, Fluorescence
D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010879:Piperazines; C515050:zopiclone; C053228:zopiclone N-oxide; C053229:N-desmethylzopiclone